

# Evan J Lipson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8605985/publications.pdf>

Version: 2024-02-01

80  
papers

15,371  
citations

87888

38  
h-index

118850

62  
g-index

82  
all docs

82  
docs citations

82  
times ranked

22609  
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. <i>Science Translational Medicine</i> , 2014, 6, 224ra24.	12.4	3,665
2	Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2014, 32, 1020-1030.	1.6	2,015
3	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 2542-2552.	27.0	1,048
4	Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. <i>New England Journal of Medicine</i> , 2022, 386, 24-34.	27.0	766
5	Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. <i>Kidney International</i> , 2016, 90, 638-647.	5.2	524
6	Evolutionary dynamics of cancer in response to targeted combination therapy. <i>ELife</i> , 2013, 2, e00747.	6.0	516
7	Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody. <i>Clinical Cancer Research</i> , 2013, 19, 462-468.	7.0	485
8	Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2011, 17, 6958-6962.	7.0	438
9	Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 24-37.	27.6	380
10	PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival. <i>Cancer Immunology Research</i> , 2013, 1, 54-63.	3.4	333
11	Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 43-50.	0.9	317
12	Cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Cardiovascular Research</i> , 2019, 115, 854-868.	3.8	311
13	Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 693-702.	1.6	274
14	Antagonists of PD-1 and PD-L1 in Cancer Treatment. <i>Seminars in Oncology</i> , 2015, 42, 587-600.	2.2	259
15	Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 916-925.	0.8	257
16	Tumor Regression and Allograft Rejection after Administration of Anti-PD-1. <i>New England Journal of Medicine</i> , 2016, 374, 896-898.	27.0	244
17	Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer. <i>JAMA Neurology</i> , 2016, 73, 928.	9.0	238
18	Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point <sup>18</sup> F-FDG PET/CT Imaging in Patients with Advanced Melanoma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1421-1428.	5.0	209

#	ARTICLE	IF	CITATIONS
19	Initial efficacy of anti-lymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-PD-1/PD-L1 therapy.. Journal of Clinical Oncology, 2017, 35, 9520-9520.	1.6	188
20	Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncology, 2015, 11, 1307-1326.	2.4	158
21	Melanoma subtypes demonstrate distinct PD-L1 expression profiles. Laboratory Investigation, 2017, 97, 1063-1071.	3.7	156
22	Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Annals of the Rheumatic Diseases, 2020, 79, 332-338.	0.9	140
23	Successful Administration of Ipilimumab to Two Kidney Transplantation Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2014, 32, e69-e71.	1.6	137
24	Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. , 2018, 6, 99.		129
25	Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. Oncologist, 2019, 24, 1259-1269.	3.7	127
26	PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison. Clinical Cancer Research, 2017, 23, 4938-4944.	7.0	120
27	Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Seminars in Arthritis and Rheumatism, 2018, 48, 553-557.	3.4	119
28	Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. , 2017, 5, 23.		118
29	Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).. Journal of Clinical Oncology, 2021, 39, 9503-9503.	1.6	116
30	Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. Science, 2021, 372, .	12.6	114
31	Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade. Clinical Cancer Research, 2020, 26, 545-551.	7.0	100
32	The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. Journal of Clinical Investigation, 2019, 129, 4305-4315.	8.2	100
33	Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. , 2015, 3, 22.		95
34	Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity. Nature Immunology, 2020, 21, 1010-1021.	14.5	85
35	Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade. Oncologist, 2017, 22, 627-630.	3.7	74
36	A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 712-720.	4.9	71

#	ARTICLE	IF	CITATIONS
37	Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis. <i>World Journal of Gastroenterology</i> , 2017, 23, 2023.	3.3	68
38	Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 3168-3180.	7.0	67
39	Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2017, 3, 974.	7.1	65
40	Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. , 2021, 9, e002478.		59
41	Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series. , 2018, 6, 104.		55
42	Chronic immune checkpoint inhibitor pneumonitis. , 2020, 8, e000840.		55
43	Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1381-1389.	3.7	54
44	Patient and graft outcomes following liver transplantation for sarcoidosis. <i>Clinical Transplantation</i> , 2005, 19, 487-491.	1.6	43
45	Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series. , 2019, 7, 170.		36
46	Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. <i>Science Immunology</i> , 2020, 5, .	11.9	36
47	Immunotherapy for Merkel cell carcinoma: a turning point in patient care. , 2018, 6, 23.		34
48	Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. , 2021, 9, e002473.		33
49	From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting. <i>Molecular Oncology</i> , 2018, 12, 1661-1672.	4.6	32
50	Re-orienting the immune system. <i>Oncoimmunology</i> , 2013, 2, e23661.	4.6	29
51	BRAF V600 mutational status affects recurrence patterns of melanoma brain metastasis. <i>International Journal of Cancer</i> , 2017, 140, 2716-2727.	5.1	24
52	Lenalidomide-Induced Acute Interstitial Nephritis. <i>Oncologist</i> , 2010, 15, 961-964.	3.7	23
53	Challenge of Rechallenge: When to Resume Immunotherapy Following an Immune-Related Adverse Event. <i>Journal of Clinical Oncology</i> , 2019, 37, 2714-2718.	1.6	23
54	A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2021, 27, 2571-2583.	7.0	22

#	ARTICLE	IF	CITATIONS
55	Surgical Resection of Malignant Melanoma Metastatic to the Pancreas: Case Series and Review of Literature. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 431-436.	1.3	21
56	Nodular Regenerative Hyperplasia Associated With Immune Checkpoint Blockade. <i>Hepatology</i> , 2018, 68, 2431-2433.	7.3	20
57	Kidney retransplantation after anti-programmed cell death-1 (PD-1)-related allograft rejection. <i>American Journal of Transplantation</i> , 2020, 20, 2264-2268.	4.7	20
58	Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma. <i>Human Pathology</i> , 2019, 91, 69-76.	2.0	14
59	A Case Report of Primary Recurrent Malignant Melanoma of the Urinary Bladder. <i>Urology Case Reports</i> , 2013, 1, 2-4.	0.3	13
60	Shorter survival and later stage at diagnosis among unmarried patients with cutaneous melanoma: A US national and tertiary care center study. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1012-1020.	1.2	13
61	A Patient with HIV Treated with Ipilimumab and Stereotactic Radiosurgery for Melanoma Metastases to the Brain. <i>Case Reports in Oncological Medicine</i> , 2013, 2013, 1-4.	0.3	12
62	Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma. , 2020, 8, e001675.		9
63	Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery. <i>Cancer Immunology Research</i> , 2021, 9, 1262-1269.	3.4	8
64	Corticosteroid Use and Pneumocystis Pneumonia Prophylaxis. <i>JAMA Internal Medicine</i> , 2018, 178, 1106.	5.1	7
65	Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures. , 2021, 9, e002345.		7
66	Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T Cells. <i>Cancer Immunology Research</i> , 2022, 10, 885-899.	3.4	7
67	Art in Oncology: How Patients Add Life to Their Days. <i>Journal of Clinical Oncology</i> , 2011, 29, 1392-1393.	1.6	6
68	The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas. <i>Clinical Cancer Research</i> , 2021, 27, 1516-1525.	7.0	6
69	Regulatory T cells—an important target for cancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 307-307.	27.6	5
70	Acute axillary lymphadenopathy detected shortly after COVID-19 vaccination found to be due to newly diagnosed metastatic melanoma. <i>Radiology Case Reports</i> , 2022, 17, 878-880.	0.6	5
71	Estimating platelet production in patients with HIV-related thrombocytopenia using the immature platelet fraction. <i>American Journal of Hematology</i> , 2009, 84, 852-854.	4.1	3
72	Poliosis Circumscripta: A Mark of Melanoma. <i>American Journal of Medicine</i> , 2019, 132, 1417-1418.	1.5	3

#	ARTICLE	IF	CITATIONS
73	Melanoma metastatic to the hyoid bone. <i>Clinical Case Reports</i> (discontinued), 2021, 9, 522-525.	0.5	2
74	The Immature Platelet Fraction in HIV Patients with Thrombocytopenia.. <i>Blood</i> , 2007, 110, 2095-2095.	1.4	1
75	Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma. <i>Cancer Immunology Research</i> , 2022, 10, 303-313.	3.4	1
76	State-of-the-Art Diagnosis and Treatment of Melanoma. <i>Journal of Computer Assisted Tomography</i> , 2018, 42, 331-339.	0.9	0
77	2568 Pembrolizumab for patients with leptomeningeal disease from advanced solid tumors. <i>Journal of Clinical and Translational Science</i> , 2018, 2, 44-45.	0.6	0
78	Further Lessons in Pneumocystis Pneumonia Prophylaxisâ€™Reply. <i>JAMA Internal Medicine</i> , 2018, 178, 1566.	5.1	0
79	Reply. <i>Hepatology</i> , 2019, 69, 2718-2719.	7.3	0
80	681â€™...Single pipeline re-analysis revises microbiome associations with anti-tumor response to checkpoint inhibitors. , 2020, , .		0